----

----

| (Mark One) |
|------------|
| þ     |   | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

| o |   | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------|------------------------------------------------------------------------------------------|

|   | WaferGen Bio-systems, Inc.                             |   |
|--------|--------------------------------------------------------|--------|
|   | (Exact Name of Registrant as Specified in its Charter) |   |

|   | Nevada                                                         |   | 90-0416683                        |   |
|--------|----------------------------------------------------------------|--------|-----------------------------------|--------|
|   | (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Identification No.) |   |

|   | 7400 Paseo Padre Parkway, Fremont, CA    |   | 94555      |   |
|--------|------------------------------------------|--------|------------|--------|
|   | (Address of principal executive offices) |   | (Zip Code) |   |

|   | (510) 651-4450                                             |   |
|--------|------------------------------------------------------------|--------|
|   | (Registrant’s telephone number, including area code) |   |

| Title of each class: None |   |   | Name of each exchange on which registered: None |
|---------------------------|--------|--------|-------------------------------------------------|
|                      |   |   |                                            |

| Common stock, $0.001 par value per share |
|------------------------------------------|
| (Title of Class)                         |

| Large accelerated filer  ̈                                                  | Accelerated filer  ̈         |
|--------------------------------------------------------------------------------------|---------------------------------------|
| Non-accelerated filer  ̈ (Do not check if a smaller reporting company) | Smaller reporting company þ |

----

----

----

----

|          |                                                                                           |   | Page     |
|---------------|------------------------------------------------------------------------------------------------|--------|----------|
|          | FORWARD LOOKING STATEMENTS                                                                     |   | 1   |   |
|          | PART III                                                                                       |   |     |   |
| ITEM 10.      | Directors, Executive Officers and Corporate Governance                                         |   | 2   |   |
| ITEM 11.      | Executive Compensation                                                                         |   | 6   |   |
| ITEM 12.      | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |   | 12  |   |
| ITEM 13.      | Certain Relationships and Related Transactions, and Director Independence                      |   | 15  |   |
| ITEM 14.      | Principal Accountant Fees and Services                                                         |   | 16  |   |
|          |                                                                                           |   |     |   |
|          | PART IV                                                                                        |   |     |   |
| ITEM 15.      | Exhibits and Financial Statement Schedules                                                     |   | 17  |   |
|          |                                                                                           |   |     |   |
| SIGNATURES    |                                                                                           |   | 21  |   |
|          |                                                                                           |   |     |   |
| EXHIBIT INDEX |                                                                                           |   | 22  |   |

----

----

Table of Contents

| Name                       |   | Age |   | Position                                                      |
|----------------------------|--------|-----|--------|---------------------------------------------------------------|
| Alnoor Shivji              |   | 55  |   | Chairman of the Board                                         |
| Robert Coradini            |   | 52  |   | Director                                                      |
| Scott Davidson             |   | 42  |   | Director                                                      |
| Dr. R. Dean Hautamaki |   | 49  |   | Director                                                      |
| Makoto Kaneshiro           |   | 53  |   | Director                                                      |
| Joel Kanter                |   | 55  |   | Director                                                      |
| Joseph Pesce               |   | 63  |   | Director                                                      |
| Dr. Timothy Triche    |   | 67  |   | Director                                                      |
| Dr. Ivan Trifunovich  |   | 49  |   | Chief Executive Officer, President and Director               |
| John Harland               |   | 60  |   | Interim Chief Financial Officer and Vice President of Finance |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Name                       |   | No. of LateReports |   | No. of Transactions ThatThat Were Not Reportedon a Timely Basis |   | Failure to File aRequired Form |
|----------------------------|--------|------------------------------|--------|--------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------|
| Robert Coradini            |   | 1                            |   | 2                                                                                                            |   | 0                                                  |
| Dr. Robert J. Hariri  |   | 2                            |   | 3                                                                                                            |   | 0                                                  |
| Dr. R. Dean Hautamaki |   | 1                            |   | 2                                                                                                            |   | 0                                                  |
| Makoto Kaneshiro           |   | 2                            |   | 4                                                                                                            |   | 0                                                  |
| Joel S. Kanter             |   | 1                            |   | 2                                                                                                            |   | 0                                                  |
| Nadine C. Smith            |   | 1                            |   | 2                                                                                                            |   | 0                                                  |

| (1) | honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | full, fair, accurate, timely, and understandable disclosure in report and document that we file with, or submit to, the Security and Exchange Commission and in other public communications made by us; |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | compliance with applicable government laws, rules and regulations; |
|-----|--------------------------------------------------------------------|

| (4) | the prompt internal reporting of violations of Code of Business Conduct and Ethics to an appropriate person or persons identified in the Code of Business Conduct and Ethics; and |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | accountability for adherence to the Code of Business Conduct and Ethics. |
|-----|--------------------------------------------------------------------------|

----

Table of Contents

|                                                                                                                                  |   | (b) Fiscal |   |   | (c) Salary |   |    | (d) Bonus |   |   | (e) StockAwards(4) |   |   | (f) OptionAwards(4) |           |   | (i) All OtherCompensation |   |           | (j) Total |   |
|---------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------|--------|--------|-----------------|--------|---------|----------------|--------|--------|-------------------------|--------|--------|--------------------------|----------------|--------|-------------------------------------|--------|----------------|----------------|--------|
| (a) Name and Principal Position                                                                                                       |   | Year            |   |   | ($)             |   |    | ($)            |   |   | ($)                     |   |   | ($)                      |           |   | ($)                                 |   |           | ($)            |   |
| Alnoor Shivji                                                                                                                         |   |            | 2011   |   |            | $      | 193,900 | (1)            |   | $      | 118,125                 |   |   | $                        | 39,375         |   |                                | $      | –– |           |   | $ | 86,964 | (1) |   | $ | 438,364 |   |
| Chairman and former President and Chief Executive Officer                                                                             |   |            | 2010   |   |            | $      | 223,125 | (1)            |   | $      | ––          |   |   | $                        | –– |   |                                | $      | –– |           |   | $ | –– |   |   | $ | 223,125 |   |
| Mona Chadha                                                                                                                           |   |            | 2011   |   |            | $      | 230,846 | (2)            |   | $      | 149,375                 |   |   | $                        | 28,125         |   |                                | $      | –– |           |   | $ | –– |   |   | $ | 408,346 |   |
| Former Office of the President, Chief Operating Officer, Executive Vice President of Marketing and Business Development and Secretary |   |            | 2010   |   |            | $      | 225,000 | (2)            |   | $      | ––          |   |   | $                        | –– |   |                                | $      | –– |           |   | $ | –– |   |   | $ | 225,000 |   |
| Donald Huffman                                                                                                                        |   |            | 2011   |   |            | $      | 225,000 | (3)            |   | $      | 49,215                  |   |   | $                        | 7,071          |   |                                | $      | –– |           |   | $ | –– |   |   | $ | 281,286 |   |
| Former Office of the President and Chief Financial Officer                                                                            |   |            | 2010   |   |            | $      | 64,038  | (3)            |   | $      | ––          |   |   | $                        | –– |   |                                | $      | 119,356        |           |   | $ | –– |   |   | $ | 183,394 |   |

| (1) | Annual salary of $262,500 commenced on May 31, 2008, one year after the date of executive officer’s employment agreement with the Company. On November 30, 2008 the Company adjusted the salary to $223,125 until the Company (a) raised $5 million in gross proceeds from the sale of its securities in one or more financings on or prior to March 30, 2009, excluding any gross proceeds received in connection with any financings completed by its Malaysian subsidiary, WGBM; or (b) raised after March 30, 2009 funds sufficient to finance the Company’s operations at its then-current burn rate for an additional nine months after the closing of such financing, as reasonably determined by the compensation committee of the board of directors of the Company. Effective May 27, 2011, the latter condition was met and the annual salary reverted to $262,500. In connection with former executive officer’s separation agreement effective October 18, 2011, the Company paid such former executive officer $52,699 in severance payments and $25,240 for accrued vacation in 2011, and will pay such former executive officer $209,801 in severance payments in 2012. Following termination as an executive officer, sums of $3,057 and $5,968 were earned in director’s fees and consultancy fees, respectively. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Such officer became a Section 16B officer on March 20, 2009, and an annual salary of $225,000 commenced on that date pursuant to such executive officer’s employment agreement with us. The annual salary was increased to $235,000 effective June 1, 2011. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (3) | Such officer became a Section 16B officer when his employment commenced on September 13, 2010, and an annual salary of $225,000 commenced on that date pursuant to such executive officer’s employment agreement with us. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Amounts in this column reflect the aggregate grant date fair value of stock awards granted in the fiscal year computed in accordance with FASB ASC Topic 718 (rather than the dollar amount recognized for financial statement purposes for the fiscal year), excluding the impact of estimated forfeitures related to service-based vesting conditions, as previously required. For more information, see Note 2, “Summary of Significant Accounting Policies—Stock-Based Compensation” and Note 8, “Stock Awards” to the Financial Statements contained in Item 8 in the Original Report. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|           |   | Number of       |    | Number of         |   |     |           |       |
|----------------|--------|----------------------|---------|------------------------|--------|----------|----------------|------------|
|           |   | Securities           |    | Securities             |   |     |           |       |
|           |   | Underlying           |    | Underlying             |   | Option   |           |       |
|           |   | Unexercised          |    | Unexercised            |   | Exercise |           | Option     |
|           |   | Options              |    | Options                |   | Price    |           | Expiration |
| Name           |   | Exercisable (#) |    | Unexercisable (#) |   | ($)      |           | Date       |
| Alnoor Shivji  |   |                 | 166,666 | (1)                    |   |     | –– | (1)        |   | $ | 1.50 |   |   | 4/18/2013 | (8) |
|           |   |                 | 75,000  | (2)                    |   |     | –– | (2)        |   | $ | 1.95 |   |   | 4/18/2013 | (8) |
|           |   |                 | 75,000  | (3)                    |   |     | –– | (3)        |   | $ | 1.35 |   |   | 4/18/2013 | (8) |
|           |   |                 | 25,000  | (4)                    |   |     | –– | (4)        |   | $  | 1.00 |   |   | 4/18/2013 | (8) |
| Mona Chadha    |   |                 | 70,189  | (5)                    |   |     | —        |       |   | $ | 0.15 |   |   | 7/1/2016 |   |
|           |   |                 | 22,917  | (2)                    |   |     | 2,083          | (2)        |   | $ | 1.95 |   |   | 4/17/2018 |   |
|           |   |                 | 40,625  | (3)                    |   |     | 9,375          | (3)        |   | $ | 1.35 |   |   | 9/30/2015 |   |
|           |   |                 | 7,917   | (4)                    |   |     | 2,083          | (4)        |   | $ | 1.00 |   |   | 10/24/2015 |   |
|           |   |                 | 171,875 | (6)                    |   |     | 78,125         | (6)        |   | $ | 1.10 |   |   | 3/20/2016 |   |
| Donald Huffman |   |                 | 62,500  | (7)                    |   |     | 137,500        | (7)        |   | $ | 1.56 |   |   | 9/13/2017 |   |

| (1) | Option to purchase shares of our common stock at an exercise price of $1.50 per share granted on May 31, 2007, which option vests in equal monthly installments over four years and expires 10 years after the date of grant. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Option to purchase shares of our common stock at an exercise price of $1.95 per share granted on April 17, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 10 years after the date of grant. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Option to purchase shares of our common stock at an exercise price of $1.35 per share granted on September 30, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous services after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Option to purchase shares of our common stock at an exercise price of $1.00 per share granted on October 24, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Option to purchase shares of our common stock at an exercise price of $0.15 per share granted on July 1, 2006, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 10 years after the date of grant. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Option to purchase our common stock at an exercise price of $1.10 per share granted on March 20, 2009, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7) | Option to purchase shares of our common stock at an exercise price of $1.56 per share granted on September 13, 2010, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (8) | In accordance with the terms of his separation agreement, all of Alnoor Shivji’s options became fully vested on October 18, 2011, and such options expire on April 18, 2013. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| (a)                                  |   | (b)              |    |   | (c)             |   |    | (d)             |   |   | (e)          |   |   | (f)            |    |   | (g)            |   |    | (h)    |   |
|--------------------------------------|--------|------------------|---------|--------|-----------------|--------|---------|-----------------|--------|--------|--------------|--------|--------|----------------|---------|--------|----------------|--------|---------|--------|--------|
|                                 |   |             |    |   |            |   |    |            |   |   |         |   |   | Change in |    |   |           |   |    |   |   |
|                                 |   |             |    |   |            |   |    |            |   |   |         |   |   | Pension        |    |   |           |   |    |   |   |
|                                 |   |             |    |   |            |   |    |            |   |   |         |   |   | Value and |    |   |           |   |    |   |   |
|                                 |   |             |    |   |            |   |    |            |   |   | Non-Equity   |   |   | Nonqualified   |    |   |           |   |    |   |   |
|                                 |   | Fees Earned |    |   |            |   |    |            |   |   | Incentive    |   |   | Deferred       |    |   |           |   |    |   |   |
|                                 |   | or Paid     |    |   | Stock           |   |    | Option          |   |   | Plan         |   |   | Compensation   |    |   | All Other |   |    |   |   |
|                                 |   | in Cash     |    |   | Awards (1) |   |    | Awards (2) |   |   | Compensation |   |   | Earnings       |    |   | Compensation   |   |    | Total  |   |
| Name                                 |   | ($)              |    |   | ($)             |   |    | ($)             |   |   | ($)          |   |   | ($)            |    |   | ($)            |   |    | ($)    |   |
| Makoto Kaneshiro                     |   | $                | 15,000  |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 37,183 |   |
| Dr. R. Dean Hautamaki |   | $                | 30,000  |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 52,183 |   |
| Joel Kanter                          |   | $                | 45,000  |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 67,183 |   |
| Dr. Robert Hariri(3)       |   | $                | 15,000  |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 37,183 |   |
| Robert Coradini                      |   | $                | 15,000  |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 37,183 |   |
| Nadine C. Smith(4)                   |   | $                | — |   |            | $      | 12,500  |            |   | $      | 9,683        |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 22,183 |   |
| Dr. Timothy Triche(5)           |   | $                | 12,500  |   |            | $      | — |            |   | $      | —      |   |   | $              | — |   |           | $      | — |   |   | $ | 64,900 |   |   | $ | 77,400 |   |

| (1) | The amounts shown in column (c) represent the aggregate grant date fair value of stock awards granted in 2011 computed in accordance with FASB ASC Topic 718. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The amounts shown in column (d) represent the aggregate grant date fair value of option awards granted in 2011 computed in accordance with FASB ASC Topic 718. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Dr. Hariri resigned from our board of directors in December 2011. The amounts included in columns (c) and (d) include $1,562 and $2,421 attributable to 1,250 restricted stock units and 5,000 stock options, respectively, that were forfeited on termination. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Ms. Smith resigned from the Board of Directors in February 2011. The amounts included in columns (c) and (d) include $6,250 and $9,683 attributable to 5,000 restricted stock units and 20,000 stock options, respectively, that were forfeited on termination. Further, the amounts included in columns (c) and (d) in 2010 included $5,738 and $8,755 attributable to 3,750 restricted stock units and 15,000 stock options, respectively, that were forfeited on termination. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Dr. Triche was appointed to our board of directors in February 2011. He was previously a member of our Scientific Advisory Board and continues to serve the Company as a consultant. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | Retainers.  Each non-employee director shall receive an annual cash retainer fee of $15,000. The chairperson of the Audit Committee, the Compensation Committee and the Clinical Development Committee shall each receive an additional annual cash retainer fee of $15,000; and |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | Annual Equity Grants.  Each non-employee director shall receive annually (i) a stock option to purchase 20,000 shares of our common stock, with 25% of the shares subject to the stock option vesting every three months, such that 100% of the shares subject to the option shall be fully vested on the one year anniversary of the date of grant (“Director Options”); and (ii) 10,000 restricted stock units, with 50% of the restricted stock units vested on the date of grant and the remaining 50% of the restricted stock units vesting every three months after the date of grant, such that 100% of the restricted stock units shall be fully vested on the one year anniversary of the date of grant (“Director RSUs”). For 2010, the Director Options and Director RSUs will be granted on the date of the Annual Meeting of Stockholders. Beginning in 2011, the Director Options and Director RSUs will be granted on the first trading day in January of each year. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|                                                       |   |               |      |                        |   | Number of       |   |
|------------------------------------------------------------|--------|--------------------|-----------|-----------------------------|--------|----------------------|--------|
|                                                       |   |               |      |                        |   | Securities           |   |
|                                                       |   |               |      |                        |   | Remaining            |   |
|                                                       |   | Number of     |      |                        |   | Available for   |   |
|                                                       |   | Securities to |      |                        |   | Future Issuance |   |
|                                                       |   | Be                 |      |                        |   | Under Equity    |   |
|                                                       |   | Issued upon   |      |                        |   | Compensation         |   |
|                                                       |   | Exercise of   |      | Weighted-Average            |   | Plans                |   |
|                                                       |   | Outstanding        |      | Exercise Price of |   | (Excluding           |   |
|                                                       |   | Options,           |      | Outstanding                 |   | Securities           |   |
|                                                       |   | Warrants and  |      | Options, Warrants      |   | Reflected in    |   |
|                                                       |   | Rights             |      | and Rights             |   | Column (a))     |   |
| Plan Category                                              |   | (a)                |      | (b)                         |   | (c)                  |   |
| Equity compensation plans approved by security holders     |   |               | 4,306,900 |                        | $      | 1.40                 |   | $ | 10,305,071 |   |
| Equity compensation plans not approved by security holders |   |               | —   |                        |   | —              |   |   | — |   |
| Total                                                      |   |               | 4,306,900 |                        | $      | 1.40                 |   | $ | 10,305,071 |   |

----

Table of Contents

|                                                                  |   | Number of |                       |       |         |   |
|-----------------------------------------------------------------------|--------|----------------|----------------------------|------------|--------------|--------|
|                                                                  |   | Shares         |                       |       | Percentage   |   |
|                                                                  |   | Beneficially   |                       |       | Beneficially |   |
| Name of Beneficial Owner                                              |   | Owned          |                       |       | Owned (1)    |   |
| 5% Holders:                                                           |   |           |                       |       |         |   |
| The Shivji Family Trust dated June 12, 2000                      |   |           | 4,837,427                  |  (2)  |         |   | 11.03 | % |
| Entities affiliated with Deerfield Management Co., L.P. Series C |   |           | 4,619,999                  |  (3)  |         |   | 9.99 | % |
| Entities affiliated with Great Point Partners, LLC                    |   |           | 4,619,999                  |  (4)  |         |   | 9.99 | % |
| Merlin Nexus III, LP                                                  |   |           | 4,619,999                  |  (5)  |         |   | 9.99 | % |
| William L. Collins                                                    |   |           | 4,340,727                  |  (6)  |         |   | 9.80 | % |
| Mark Tompkins                                                         |   |           | 2,481,083                  |  (7)  |         |   | 5.88 | % |
| Directors and Executive Officers:                                     |   |           |                       |       |         |   |   |   |
| Alnoor Shivji                                                         |   |           | 8,614,060                  |  (8)  |         |   | 19.16 | % |
| Robert Coradini                                                       |   |           | 1,463,862                  |  (9)  |         |   | 3.42 | % |
| Joel Kanter                                                           |   |           | 796,027                    |  (10) |         |   | 1.88 | % |
| Dr. R. Dean Hautamaki                                            |   |           | 728,193                    |  (11) |         |   | 1.73 | % |
| Makoto Kaneshiro                                                      |   |           | 141,250                    |  (12) |         |   | * |   |
| Dr. Timothy Triche                                               |   |           | 134,250                    |  (13) |         |   | * |   |
| Scott Davidson                                                        |   |           | ––             |  (14) |         |   | –– |   |
| Joseph Pesce                                                          |   |           | ­­–– |  (14) |         |   | –– |   |
| Ivan Trifunovich                                                      |   |           | ––             |  (15) |         |   | –– |   |
| John Harland                                                          |   |           | ––             |  (16) |         |   | ­­–– |   |
| Directors and Executive Officers as a Group (10 persons)              |   |           | 11,877,642                 |       |         |   | 24.98 | % |

| * | Less than 1% |
|---|--------------|

| (1) | Based on 41,649,402 shares of our common stock issued and outstanding as of March 31, 2012. |
|-----|--------------------------------------------------------------------------------------------------|

| (2) | Includes 384,615 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock, 365,970 shares of common stock issuable on conversion of Convertible Promissory Notes and 1,473,290 shares of common stock issuable upon the exercise of currently exercisable warrants. Alnoor Shivji and his wife, Mariam Shivji, are the co-trustees of The Shivji Family Trust dated June 12, 2000 (“The Shivji Family Trust”). Its address is 692 Hillcrest Terrace, Fremont, CA 94539. See also footnote (8) in this section. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Consists of 4,619,999 shares of common stock issuable upon conversion of Series A-1 Convertible Preferred Stock collectively owned by each of Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations Fund International, Limited (collectively, the “Deerfield Owners”). Does not include (i) 8,360,769 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock, (ii) 12,351,508 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes, and (iii) 24,822,876 shares of common stock issuable upon the exercise of warrants collectively owned by the Deerfield Owners. The provisions of such preferred stock and warrants restrict the conversion and exercise, respectively, of such preferred stock and warrants to the extent that, after giving effect to such conversion or exercise, the holder of the preferred stock and warrants and its affiliates and any other person or entities with which such holder would constitute a group would beneficially own in excess of 9.985% and 9.98%, respectively, of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to such conversion or exercise, respectively (the “Ownership Cap”). Therefore, the reporting persons could be deemed to beneficially own such number of shares underlying such preferred stock and warrants as would result in total beneficial ownership by such reporting persons up to the Ownership Cap of 9.985%. James E. Flynn has the power to vote or dispose of the securities held by each of the Deerfield Owners, and his address is c/o Deerfield Management Co., L.P. Series C, 780 Third Avenue, 37th Floor, New York, NY 10017. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (4) | Consists of 4,619,999 shares of common stock issuable upon conversion of Series A-1 Convertible Preferred Stock collectively owned by each of Biomedical Value Fund, LP (“BVF”), Biomedical Offshore Value Fund, Limited (“BOVF”), Biomedical Institutional Value Fund, LP (“BIVF”), Lyrical Multi-Manager Fund, LP (“Lyrical”), Class D Series of GEF-PS, LP (“GEF-PS”), David J. Morrison (“Morrison”), WS Investments III, LLC (“WS”), Thomas C. Jay QPERT (“QPERT”), Carolyn Jay Trust (“Carolyn Trust”), Jeffrey Jay Jr. Trust (“Jay Trust”) and Jeffrey and Mary Ellen Jay (“Jay,” and together with QPERT, Carolyn Trust and Jay Trust, the “Jay Owners”). Does not include (i) 8,120,390 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock, (ii) 12,122,773 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes, and (iii) 24,363,196 shares of common stock issuable upon the exercise of warrants collectively owned by each of BVF, BOVF, BIVF, Lyrical, GEF-PS, Morrison, WS and the Jay Owners, the conversion or exercise of which would result in total beneficial ownership by such reporting persons exceeding the Ownership Cap of 9.985%. Great Point Partners, LLC is the investment manager with respect to the shares beneficially owned by each of BVF, BOVF, BIVF, Lyrical, GEF-PS, Morrison, and WS. Jeffrey R. Jay has the sole voting and sole dispositive power with respect to the shares beneficially owned by the Jay Owners. All of these funds are administered by Great Point Partners, LLC, whose address is 165 Mason Street, 3rd Floor, Greenwich, CT 06830. See also footnote (14) in this section. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Consists of (i) 2,403,846 shares of common stock issuable upon conversion of Series A-1 Convertible Preferred Stock, and (ii) 2,216,153 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes. Does not include (i) 71,163 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes, and (ii) 4,596,829 shares of common stock issuable upon the exercise of warrants, the exercise of which would result in total beneficial ownership by such reporting person exceeding the Ownership Cap of 9.985%. The address of Merlin Nexus III, LP is 424 West 33rd Street, Suite 520, New York, NY 10001. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Includes 1,600,000 shares held by William L. Collins 2009 GRAT, 7,736 shares held by affiliates of Brencourt Advisors, LLC, 1,230,770 shares of common stock issuable upon the exercise of currently exercisable warrants held by William L. Collins 2009 GRAT and 1,427,339 shares of common stock issuable upon the exercise of currently exercisable warrants held by affiliates of Brencourt Advisors, LLC. William L. Collins has voting control and investment power over, but disclaims beneficial ownership of, the securities managed owned by William L. Collins 2009 GRAT. William L. Collins is the CEO and Managing Member of Brencourt Advisors, LLC, but lacks sole voting control and investment power over and disclaims beneficial ownership of the securities managed by Brencourt Advisors, LLC. Brencourt Advisors, LLC’s and William L. Collins’s address is 600 Lexington Avenue, 8th Floor, New York, NY 10022. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7) | Share ownership based on beneficial owner’s Schedule 13G filed on May 9, 2011. Includes 517,457 shares of common stock issuable upon the exercise of currently exercisable warrants. His address is c/o Gottbetter & Partners, 488 Madison Ave, 12th Floor, New York, NY 10022. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (8) | Consists of (i) 2,549,529 shares of common stock, (ii) 659,786 shares of common stock issuable upon the exercise of currently exercisable warrants, (iii) 1,250 shares of restricted stock that will vest within 60 days, (iv) 346,666 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (v) 2,613,552 shares of common stock held by The Shivji Family Trust, (vi) 384,615 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock held by The Shivji Family Trust, (vii) 365,970 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes held by The Shivji Family Trust, (viii) 1,473,290 shares of common stock issuable upon the exercise of currently exercisable warrants held by The Shivji Family Trust, (ix) 48,333 shares of common stock held by each of the Shivji Children’s Trust fbo Zahra Shivji, the Shivji Children’s Trust fbo Suraya Shivji and the Jameel Shivji Irrevocable Trust (the “Shivji Children’s Trusts”), and (x) 24,801 shares of common stock issuable upon the exercise of currently exercisable warrants held by each of the three Shivji Children’s Trusts. Mr. Shivji and his wife, Mariam Shivji, are the co-trustees of The Shivji Family Trust and each of the three Shivji Children’s Trusts (together, the “Shivji Trusts”). Mr. Shivji disclaims beneficial ownership of the securities held by each of the Shivji Trusts, except to the extent he has a pecuniary interest therein. Excludes 3,750 shares of restricted stock that will not vest within 60 days and options to purchase 15,000 shares of common stock that are not exercisable within 60 days. See also footnote (2) in this section. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9) | Consists of (i) 309,391 shares of common stock, (ii) 240,384 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock, (iii) 228,731 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes, (iv) 599,106 shares of common stock issuable upon the exercise of currently exercisable warrants, (v) 1,250 shares of restricted stock that will vest within 60 days, and (vi) 85,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (10) | Consists of (i) 25,000 shares of common stock, (ii) 96,153 shares of common stock issuable on conversion of Series A-1 Convertible Preferred Stock, (iii) 91,492 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes, (iv) 183,873 shares of common stock issuable upon the exercise of currently exercisable warrants, (v) 1,250 shares of restricted stock that will vest within 60 days, (vi) 115,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (vii) 75,000 shares of common stock held by the Kanter Family Foundation, (viii) 48,076 shares of common stock issuable on conversion of Series A-1 Preferred Stock held by the Kanter Family Foundation, (ix) 45,746 shares of common stock issuable on conversion of Series A-2 Convertible Preferred Stock on conversion of Convertible Promissory Notes held by the Kanter Family Foundation, and (x) 114,437 shares of common stock issuable upon exercise of currently exercisable warrants held by the Kanter Family Foundation. Mr. Kanter has voting control and investment power over, but disclaims beneficial ownership of, the securities owned by the Kanter Family Foundation. Excludes 3,750 shares of restricted stock that will not vest within 60 days and options to purchase 15,000 shares of common stock that are not exercisable within 60 days. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (11) | Consists of (i) 8,750 shares of common stock, (ii) 1,250 shares of restricted stock that will vest within 60 days, (iii) 395,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (iv) 226,883 shares of common stock held by Cojack Investment Opportunities, LLC (“Cojack”), and (v) 96,310 shares of common stock issuable upon the exercise of currently exercisable warrants held by Cojack. Excludes 3,750 shares of restricted stock that will not vest within 60 days and options to purchase 15,000 shares of common stock that are not exercisable within 60 days. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (12) | Consists of (i) 25,000 shares of common stock, (ii) 1,250 shares of restricted stock that will vest within 60 days, and (iii) 115,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes 3,750 shares of restricted stock that will not vest within 60 days and options to purchase 15,000 shares of common stock that are not exercisable within 60 days. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (13) | Consists of (i) 5,000 shares of common stock, (ii) 1,250 shares of restricted stock that will vest within 60 days, and (iii) 128,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes 3,750 shares of restricted stock that will not vest within 60 days and options to purchase 40,000 shares of common stock that are not exercisable within 60 days. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (14) | Scott Davidson and Joseph Pesce do not beneficially own any shares of WaferGen Bio-systems, Inc. Both are managing directors of Great Point Partners, LLC, whose interests are recorded in footnote (4) in this section. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (15) | Excludes options to purchase 3,000,000 shares of common stock that are not exercisable within 60 days. |
|------|--------------------------------------------------------------------------------------------------------|

| (16) | Excludes options to purchase 70,000 shares of common stock that are not exercisable within 60 days. |
|------|-----------------------------------------------------------------------------------------------------|

----

Table of Contents

|               |   | 2011   |    |   | 2010   |   |
|--------------------|--------|--------|---------|--------|--------|--------|
| Audit fees         |   | $      | 270,468 |   |   | $      | 193,499 |   |
| Audit related fees |   |   | 44,496  |   |   |   | 16,914 |   |
| Tax fees           |   |   | 9,166   |   |   |   | 14,974 |   |
| All other fees     |   |   | — |   |   |   | — |   |
| Total Fees         |   | $      | 324,130 |   |   | $      | 225,387 |   |

----

Table of Contents

|   | • | should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------|

|   | • | were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|          |   |                                                                                                                                              |   |          |   | Incorporated by Reference |
|---------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                               |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 2.1           |   | Agreement and Plan of Merger and Reorganization, dated as of May 31, 2007, by and among WBSI, WaferGen Acquisition Corp., and WaferGen, Inc. |   |          |   | 8-K                       |   |   |   | 2.1 |   | 6/5/2007 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 2.2           |   | Certificate of Merger of WaferGen Acquisition Corp. with and into WaferGen, Inc., dated May 31, 2007                                         |   |          |   | 8-K                       |   |   |   | 2.2 |   | 1/16/2008 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.1           |   | Certificate of Incorporation of WBSI                                                                                                              |   |          |   | SB-2                      |   |   |   | 3.1 |   | 8/9/2006 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.2           |   | Certificate of Amendment to the Certificate of Incorporation of WBSI, dated January 31, 2007                                                 |   |          |   | 8-K                       |   |   |   | 3.1 |   | 2/1/2007 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.3           |   | Bylaws of WBSI                                                                                                                                    |   |          |   | SB-2                      |   |   |   | 3.2 |   | 8/9/2006 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.4           |   | Certificate of Designation of Preferences, Rights and Limitations of Series A-1 and Series A-2 Convertible Preferred Stock                        |   |          |   | 8-K                       |   |   |   | 3.1 |   | 6/1/2011 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.5           |   | First Amendment to Bylaws of WBSI                                                                                                                 |   |          |   | 8-K                       |   |   |   | 3.2 |   | 6/1/2011 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.3           |   | Second Amendment to Bylaws of WBSI                                                                                                                |   |          |   | 8-K                       |   |   |   | 3.2 |   | 10/19/2011 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 10.1 †  |   | Form of Warrants, made as of May 5, 2007, to purchase up to an aggregate of 115,424 shares of WBSI’s Common Stock                      |   |          |   | 10-K                      |   | 12/31/09 |   | 10.1 |   | 3/22/10 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 10.2          |   | Form of Common Stock Purchase Warrant issued to investors in a private placement, the initial closing of which was held on May 31, 2007      |   |          |   | 8-K                       |   |   |   | 10.21 |   | 6/5/2007 |

----

Table of Contents

|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   | Incorporated by Reference |
|---------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                                                                                                          |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.3          |   | Form of Warrant issued to Placement Agent in connection with a private placement, the initial closing of which was held on May 31, 2007                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.22 |   | 6/5/2007 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.4 †  |   | Employment Agreement dated May 31, 2007, between WBSI and Alnoor Shivji                                                                                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.26 |   | 6/5/2007 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.5          |   | Securities Purchase Agreement, dated May 19, 2008, by and among WaferGen Bio-systems, Inc. and the purchasers identified on the signature pages thereto                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.1 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.6          |   | Form of Common Stock Purchase Warrant issued to investors identified in the Securities Purchase Agreement dated May 19, 2008                                                                                                                                                                            |   |          |   | 8-K                       |   |   |   | 10.2 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.7 †  |   | WaferGen Bio-systems, Inc. 2008 Stock Incentive Plan, as amended                                                                                                                                                                                                                                             |   |          |   | 8-K                       |   |   |   | 10.1 |   | 1/5/2012 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.8 †  |   | Form of Non-Qualified Stock Option award under 2008 Stock Incentive Plan                                                                                                                                                                                                                                     |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.35 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.9          |   | Share Subscription Agreement and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., Malaysian Technology Development Corporation Sdn. Bhd. and WaferGen Biosystems (M) Sdn. Bhd.                                                                                 |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.1 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.10         |   | Put Agreement dated May 28, 2008, by and among WaferGen Bio-systems, Inc. and Holders of the Series A Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                     |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.2 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.11         |   | Put Option Agreement dated May 28, 2008, by and among Alnoor Shivji and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                          |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.3 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.12 † |   | Letter Agreement dated January 16, 2009, by and between WBSI and Alnoor Shivji                                                                                                                                                                                                                          |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.39 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.13         |   | Form of WBSI Distribution Agreement                                                                                                                                                                                                                                                                          |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.42 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.14         |   | Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd. and Expedient Equity Ventures Sdn. Bhd.                                                                                                        |   |          |   | 8-K                       |   |   |   | 10.1 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.15         |   | Put Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                        |   |          |   | 8-K                       |   |   |   | 10.2 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.16         |   | Form of Put Option Agreement dated April 3, 2009, by and among Alnoor Shivji and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                      |   |          |   | 8-K                       |   |   |   | 10.3 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.17         |   | Deed of Adherence to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd. and Malaysian Technology Development Corporation Sdn. Bhd. |   |          |   | 10-Q                      |   | 3/31/2009 |   | 10.4 |   | 5/12/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.18         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                                             |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.5 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.19         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued June 16, 2009, to investors in the Company’s 2009 private placement offering of units of securities                                                                                                                    |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.6 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.20         |   | Registration Rights Agreement, dated June 16, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                   |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.7 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.21         |   | Form of Warrant to purchase shares of Common Stock of the Company, issued to Spencer Trask Ventures, Inc. and certain related parties in connection with the Company’s 2009 private placement offering of units of securities                                                                          |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.8 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.22         |   | Share Subscription Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                        |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.1 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.23         |   | Put Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                         |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.2 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |

----

Table of Contents

|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   | Incorporated by Reference |
|---------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                    |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.24         |   | Put Option Agreement dated July 1, 2009, by and among Alnoor Shivji and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                                                                                                                                                                                                          |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.3 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.25         |   | Deed of Adherence dated July 1, 2009, to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, and the Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd., Malaysian Technology Development Corporation Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd. |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.4 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.26 † |   | Employment Agreement, effective October 29, 2009, by and between the Company and Mona Chadha                                                                                                                                                                                                                                                                                                                                      |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.5 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.27         |   | Lease Agreement by and between WaferGen, Inc. and LBA Realty Fund III-Company VII, LLC dated October 22, 2009                                                                                                                                                                                                                                                                                                                     |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.6 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.28         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                   |   |          |   | S-1                       |   |   |   | 10.58 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.29         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued December 23, 2009, to investors in the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                      |   |          |   | S-1                       |   |   |   | 10.59 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.30         |   | Registration Rights Agreement, dated December 23, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                     |   |          |   | S-1                       |   |   |   | 10.60 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.31         |   | Securities Purchase Agreement, dated July 1, 2010, between WaferGen Bio-systems, Inc. and each investor party thereto in connection with the Company’s July 2010 offering of units of securities                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 10.1 |   | 7/8/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.32         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued July 7, 2010, to investors in the Company’s July 2010 offering of units of securities                                                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 4.1 |   | 7/8/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.33         |   | Form of Warrant to purchase shares of Common Stock of the Company, issued July 7, 2010, to placement agents and certain related parties in connection with the Company’s July 2010 offering of units of securities                                                                                                                                                                                                     |   |          |   | 10-Q                      |   | 6/30/2010  |   | 10.3 |   | 8/16/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.34 † |   | Employment Agreement, effective September 3, 2010, by and between the Company and Donald Huffman                                                                                                                                                                                                                                                                                                                                  |   |          |   | 10-Q                      |   | 9/30/2010  |   | 10.2 |   | 11/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.35         |   | Loan and Security Agreement, dated December 7, 2010, between Oxford Finance Corporation, Wafergen Inc. and WaferGen Bio-systems, Inc.                                                                                                                                                                                                                                                                                             |   |          |   | 8-K                       |   |   |   | 10.1 |   | 12/13/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.36         |   | Warrant to purchase shares of Common Stock of the Company, issued December 7, 2010, to Oxford Finance Corporation                                                                                                                                                                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.2 |   | 12/13/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.37         |   | Share Subscription Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd. and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 10.1 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.38         |   | Put Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc. and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                                                                                                                                         |   |          |   | 8-K                       |   |   |   | 10.2 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.39         |   | Amended and Restated Shareholders’ Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Malaysian Technology Development Corporation Sdn. Bhd. and Prima Mahawangsa Sdn. Bhd.                                                                                                                                                                                     |   |          |   | 8-K                       |   |   |   | 10.3 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.40         |   | Purchase Agreement, dated as of May 25, 2011, by and among WaferGen Bio-systems, Inc. and the investors signatory thereto                                                                                                                                                                                                                                                                                                         |   |          |   | 8-K                       |   |   |   | 10.1 |   | 6/1/2011 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.41         |   | Registration Rights Agreement, dated as of May 27, 2011, by and among WaferGen Bio-systems, Inc. and the purchasers signatory thereto                                                                                                                                                                                                                                                                                             |   |          |   | 8-K                       |   |   |   | 10.2 |   | 6/1/2011 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.42         |   | Form of Convertible Promissory Notes, issued May 27, 2011, to investors in the Company’s May 2011 private placement offering                                                                                                                                                                                                                                                                                           |   |          |   | 8-K                       |   |   |   | 10.3 |   | 6/1/2011 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.43         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued May 27, 2011, to investors in the Company’s May 2011 private placement offering                                                                                                                                                                                                                                                             |   |          |   | 8-K                       |   |   |   | 10.4 |   | 6/1/2011 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |

----

Table of Contents

|           |   |                                                                                                                                                                                                                                                               |   |          |   | Incorporated by Reference |
|----------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber  |   | Exhibit Description                                                                                                                                                                                                                                                |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.44          |   | Letter Agreement, dated as of May 27, 2011, by and among WaferGen Bio-systems, Inc. and the investors signatory thereto                                                                                                                                       |   |          |   | 10-Q                      |   | 6/30/2011  |   | 10.1 |   | 9/12/2011 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.45          |   | Omnibus Amendment No. 1 to Convertible Promissory Notes, dated as of September 30, 2011, by and among WaferGen Bio-systems, Inc. and the investors signatory thereto                                                                                     |   |          |   | 8-K                       |   |   |   | 10.1 |   | 10/6/2011 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.46          |   | Termination Letter, dated as of September 30, 2011, by and among WaferGen Bio-systems, Inc. and the parties signatory thereto                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.3 |   | 10/6/2011 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10. 47 † |   | Employment Separation Agreement, dated October 19, 2011 by and among Alnoor Shivji and WaferGen Bio-systems, Inc.                                                                                                                                             |   |          |   | 10-Q                      |   | 9/30/2011  |   | 10.7 |   | 11/21/2011 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.48          |   | Letter Agreement Regarding Extension of Time to Exercise Put Option and Related Matters, entered into on December 9, 2011, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn Bhd and Malaysian Technology Development Corporation Sdn Bhd. |   |          |   | 8-K                       |   |   |   | 10.1 |   | 12/15/2011 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.49          |   | Letter Agreement, dated as of January 12, 2012, by and among WaferGen Bio-systems, Inc. and the parties signatory thereto                                                                                                                                     |   |          |   | 8-K                       |   |   |   | 10.1 |   | 1/13/2012 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 10.50 †  |   | Executive Employment Agreement, dated as of March 8, 2012, by and between Ivan Trifunovich and WaferGen Bio-systems, Inc.                                                                                                                                     |   |          |   | 8-K                       |   |   |   | 10.1 |   | 3/9/2012 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 21.1           |   | Subsidiaries of the Registrant                                                                                                                                                                                                                                     |   |          |   | 10-K                      |   | 12/31/11 |   | 21.1 |   | 3/23/2012 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 23.1           |   | Consent of Independent Registered Public Accounting Firm                                                                                                                                                                                                           |   |          |   | 10-K                      |   | 12/31/11 |   | 23.1 |   | 3/23/2012 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |
| 23.2           |   | Consent of Independent Registered Public Accounting Firm                                                                                                                                                                                                           |   |          |   | 10-K                      |   | 12/31/11 |   | 23.2 |   | 3/23/2012 |
|           |   |                                                                                                                                                                                                                                                               |   |          |   |                      |   |   |   |   |   |   |

| 31.1       |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |   | 10-K   |   | 12/31/11 |   | 31.1   |   | 3/23/2012 |
|------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|----------|--------|--------|--------|-----------|
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 31.2       |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |   | 10-K   |   | 12/31/11 |   | 31.2   |   | 3/23/2012 |
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 31.3       |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   | X      |   |   |   |     |   |   |   |      |
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 31.4       |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |   | X      |   |   |   |     |   |   |   |      |
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 32.1       |   | Section 1350 Certification of principal executive officer (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.)                                                                                                                                                                                                         |   |   |   | 10-K   |   | 12/31/11 |   | 32.1   |   | 3/23/2012 |
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 32.2       |   | Section 1350 Certification of principal financial officer (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.)                                                                                                                                                                                                         |   |   |   | 10-K   |   | 12/31/11 |   | 32.2   |   | 3/23/2012 |
|       |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   |   |   |   |   |     |   |   |   |      |
| 101 § |   | The following financial information from the Company’s Annual Report on Form 10-K for the period ended December 31, 2011, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets at December 31, 2011 and 2010, (ii) the Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2011 and 2010, (iii) the Consolidated Statements of Stockholders’ Equity (Deficit) for the two years ended December 31, 2011, (iv) the Consolidated Statements of Cash Flows for the years ended December 31, 2011 and 2010, and (v) Notes to Consolidated Financial Statements |   |   |   | 10-K   |   | 12/31/11 |   | 101    |   | 3/23/2012 |

| † |   | Indicates a management contract or compensatory plan or arrangement. |
|---------|--------|----------------------------------------------------------------------|

| §  |   | Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Annual Report on Form 10-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filings. |
|--------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|                      |   | WAFERGEN BIO-SYSTEMS, INC.    |   |
|---------------------------|--------|----------------------------------------------|--------|
|                      | By:    | /s/ IVAN TRIFUNOVICH                    |   |
| Date: April 27, 2012 |   | Ivan Trifunovich                             |   |
|                      |   | Chief Executive Officer and President        |   |

| SIGNATURE                             |   | TITLE                                                         |   | DATE                |
|---------------------------------------|--------|---------------------------------------------------------------|--------|---------------------|
| /s/ IVAN TRIFUNOVICH             |   |   Chief Executive Officer and President             |   | April 27, 2012 |
| Ivan Trifunovich                      |   | (Principal Executive Officer)                            |   |                |
| /s/ JOHN HARLAND            |   | Interim Chief Financial Officer andVice President of Finance  |   | April 27, 2012 |
| John Harland                          |   | (Principal Financial Officer andPrincipal Accounting Officer) |   |                |
|                                  |   |                                                          |   |                |
| /s/ ALNOOR SHIVJI           |   | Chairman of the Board                                         |   | April 27, 2012 |
| Alnoor Shivji                         |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ ROBERT CORADINI         |   | Director                                                      |   | April 27, 2012 |
| Robert Coradini                       |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ SCOTT DAVIDSON          |   | Director                                                      |   | April 27, 2012 |
| Scott Davidson                        |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
|                                  |   | Director                                                      |   |                |
| Dr. R. Dean Hautamaki            |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ MAKOTO KANESHIRO             |   | Director                                                      |   | April 27, 2012 |
| Makoto Kaneshiro                      |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ JOEL KANTER                  |   | Director                                                      |   | April 27, 2012 |
| Joel Kanter                           |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ JOSEPH PESCE            |   | Director                                                      |   | April 27, 2012 |
| Joseph Pesce                          |   |                                                          |   |                |
|                                  |   |                                                          |   |                |
| /s/ DR. TIMOTHY TRICHE |   | Director                                                      |   | April 27, 2012 |
| Dr. Timothy Triche               |   |                                                          |   |                |

----

Table of Contents

| Exhibit No. |   | Description                                                                |
|-------------|--------|----------------------------------------------------------------------------|
|        |   |                                                                       |
| 31.3        |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer |
|        |   |                                                                       |
| 31.4        |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer |

----